Compare Ascendis Pharma A/S (ASND) vs Diamondback Energy Inc (FANG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Diamondback Energy Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Diamondback Energy Inc trades at $186.23 (market cap $51.59B). The key difference: Diamondback Energy Inc is far larger — about 2.9× Ascendis Pharma A/S's market cap, and Diamondback Energy Inc pays a 2.4% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | FANG | |
|---|---|---|
Market Cap | $17.74B | $51.59B |
Sector | Health | Energy |
52-Week High | $277.18 | $213.69 |
52-Week Low | $163.32 | $134.53 |
Enterprise Value | $18.11B | $65.31B |
Dividend Yield | — | 2.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Diamondback Energy (FANG) trades at $183.39, up 0.76% on the day, with a bearish technical signal and neutral oscillators. The company reported mixed Q1 2026 earnings, beating estimates with EPS of $4.23 versus $3.74 expected, but missed Q4 2025. Revenue grew to $14.93B in 2025, though net income margin compressed to 1.88%. Analyst consensus remains strongly bullish with a $234.50 price target, while recent news highlights sector volatility amid oil price fluctuations and upcoming Q2 2026 earnings on August 3, 2026.
FANG presents a growth opportunity with strong analyst support and expanding revenue, but faces risks from declining profit margins, high P/E of 187.13, and oil market sensitivity. The stock's 22% upside to consensus target is tempered by execution risks and macroeconomic headwinds, requiring careful monitoring of Q2 earnings and oil price trends for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →
